{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T06:48:18Z","timestamp":1775198898377,"version":"3.50.1"},"reference-count":45,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Institution of Corresponding Author","award":["Organization Internal Funding"],"award-info":[{"award-number":["Organization Internal Funding"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Multiple myeloma (MM) is an incurable plasma cell neoplasm in which diagnosis and prognostication rely on invasive bone marrow examinations that may not capture biological heterogeneity across different disease sites. There is a clinical need for non-invasive biomarkers that can accurately predict treatment outcomes. Methods: We performed a global proteomic profiling of bone marrow-derived extracellular vesicles (EVs) from nine MM patients and ten controls. A total of 8839 proteins were identified, of which 14 met predefined selection criteria. These candidates were quantified in serum-derived EVs using targeted proteomic analysis. Prognostic relevance of selected proteins was evaluated in newly diagnosed MM (NDMM) patients treated with daratumumab-containing frontline regimens (n = 26) and healthy individuals (n = 60). Progression-free survival (PFS) was analyzed using univariable and multivariable models. Results: IL5RA (p = 0.003) and BCMA (p &lt; 0.001) were significantly elevated in serum EVs from MM patients compared with controls. Higher serum EV-IL5RA and EV-BCMA were associated with a trend toward shorter PFS. Combined assessment of these biomarkers enabled clear stratification of MM patients into three prognostic groups, including a cohort with markedly inferior outcomes, with a 20-month PFS of 0 (p = 0.001). In multivariable analysis, the combined serum EV-IL5RA and EV-BCMA signature suggests an independent prognostic potential (HR = 38.49 [95% CI, 1.51\u201347.79], p = 0.015). Conclusions: Serum EV-IL5RA and EV-BCMA are novel non-invasive biomarkers, measurable through routine blood testing, with strong potential to improve risk stratification in NDMM patients in the era of daratumumab-based frontline therapy.<\/jats:p>","DOI":"10.3390\/cancers18071116","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T13:41:53Z","timestamp":1774878113000},"page":"1116","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Extracellular Vesicle IL5RA and BCMA in Serum Enable Non-Invasive Risk Stratification of Multiple Myeloma"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0945-2030","authenticated-orcid":false,"given":"Yuko","family":"Shirouchi","sequence":"first","affiliation":[{"name":"Division of Analytical Biochemistry, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo 135-8550, Japan"},{"name":"Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo 135-8550, Japan"},{"name":"Cancer Bioscience\/Oncotherapeutic Medicine, Tohoku University School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Miyagi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Shinchi","sequence":"additional","affiliation":[{"name":"Division of Analytical Biochemistry, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo 135-8550, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7861-617X","authenticated-orcid":false,"given":"Yoshimi","family":"Haga","sequence":"additional","affiliation":[{"name":"Division of Analytical Biochemistry, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo 135-8550, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Mishima","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo 135-8550, Japan"},{"name":"The Cancer Chemotherapy Center, Division of Clinical Research, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo 135-8550, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayuri","family":"Minowa","sequence":"additional","affiliation":[{"name":"The Cancer Chemotherapy Center, Division of Clinical Research, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo 135-8550, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Takayama","sequence":"additional","affiliation":[{"name":"The Cancer Chemotherapy Center, Division of Clinical Research, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo 135-8550, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5031-1953","authenticated-orcid":false,"given":"Shunji","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Cancer Bioscience\/Oncotherapeutic Medicine, Tohoku University School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Miyagi, Japan"},{"name":"Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo 135-8550, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0654-6920","authenticated-orcid":false,"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo 135-8550, Japan"},{"name":"The Cancer Chemotherapy Center, Division of Clinical Research, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo 135-8550, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9066-4959","authenticated-orcid":false,"given":"Koji","family":"Ueda","sequence":"additional","affiliation":[{"name":"Division of Analytical Biochemistry, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo 135-8550, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"ref_1","unstructured":"Cancer Information Service of National Cancer Center (2024, May 18). Projected Cancer Statistics. Available online: https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/short_pred_en.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/bjh.16674","article-title":"Incidence and survival of multiple myeloma: A population-based study of 10 524 patients diagnosed 1982\u20132017","volume":"191","author":"Langseth","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.33696\/haematology.4.055","article-title":"Analysis of Updates in Multiple Myeloma Treatment and Management","volume":"4","author":"Nieto","year":"2023","journal-title":"J. Clin. Haematol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Uno, S., Midorikawa, S., Inoue, K., Ichikawa, D., Ito, T., Kuroda, J., and Suzuki, K. (2023). Survival outcomes among patients with multiple myeloma in the era of novel agents: Exploratory assessment using an electronic medical record database in Japan. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0285947"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s12185-024-03754-8","article-title":"Primary analysis of a prospective cohort study of Japanese patients with plasma cell neoplasms in the novel drug era (2016\u20132021)","volume":"119","author":"Shibayama","year":"2024","journal-title":"Int. J. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41375-024-02505-2","article-title":"Daratumumab\/lenalidomide\/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes","volume":"39","author":"Facon","year":"2025","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S1470-2045(25)00018-X","article-title":"Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): Final analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"26","author":"Mateos","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group","volume":"121","author":"Group","year":"2003","journal-title":"Br. J. Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A Report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.cell.2016.01.043","article-title":"Communication by Extracellular Vesicles: Where We Are and Where We Need to Go","volume":"164","author":"Tkach","year":"2016","journal-title":"Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41392-020-00261-0","article-title":"Exosomes: Key players in cancer and potential therapeutic strategy","volume":"5","author":"Dai","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Irmer, B., Chandrabalan, S., Maas, L., Bleckmann, A., and Menck, K. (2023). Extracellular Vesicles in Liquid Biopsies as Biomarkers for Solid Tumors. Cancers, 15.","DOI":"10.3390\/cancers15041307"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"103365","DOI":"10.1016\/j.ebiom.2021.103365","article-title":"Circulating extracellular vesicles are effective biomarkers for predicting response to cancer therapy","volume":"67","author":"Zhou","year":"2021","journal-title":"eBioMedicine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.immuni.2010.11.013","article-title":"Mzb1 protein regulates calcium homeostasis, antibody secretion, and integrin activation in innate-like B cells","volume":"33","author":"Flach","year":"2010","journal-title":"Immunity"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3892\/ijo.2020.5056","article-title":"Proteomics and functional study reveal marginal zone B and B1 cell specific protein as a candidate marker of multiple myeloma","volume":"57","author":"Chanukuppa","year":"2020","journal-title":"Int. J. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"8528","DOI":"10.1038\/s41598-023-35378-z","article-title":"IL5RA as an immunogenic cell death-related predictor in progression and therapeutic response of multiple myeloma","volume":"13","author":"Xu","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1073\/pnas.0811591106","article-title":"pERp1 is significantly up-regulated during plasma cell differentiation and contributes to the oxidative folding of immunoglobulin","volume":"106","author":"Shimizu","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"17019","DOI":"10.1073\/pnas.0903036106","article-title":"Efficient IgM assembly and secretion require the plasma cell induced endoplasmic reticulum protein pERp1","volume":"106","author":"Pena","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1084\/jem.175.2.341","article-title":"Molecular cloning and expression of the human interleukin 5 receptor","volume":"175","author":"Murata","year":"1992","journal-title":"J. Exp. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-2567.2006.02382.x","article-title":"Interleukin-5 regulates genes involved in B-cell terminal maturation","volume":"118","author":"Horikawa","year":"2006","journal-title":"Immunology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1182\/blood.V79.12.3101.bloodjournal79123101","article-title":"Interleukin-5, eosinophils, and disease","volume":"79","author":"Sanderson","year":"1992","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/nrd2637","article-title":"Directing cancer cells to self-destruct with pro-apoptotic receptor agonists","volume":"7","author":"Ashkenazi","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood.V98.3.795","article-title":"TRAIL\/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: Therapeutic applications","volume":"98","author":"Mitsiades","year":"2001","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","article-title":"Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival","volume":"158","author":"Sanchez","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3324\/haematol.2016.150896","article-title":"Serum B-cell maturation antigen: A novel biomarker to predict outcomes for multiple myeloma patients","volume":"102","author":"Ghermezi","year":"2017","journal-title":"Haematologica"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Wiedemann, \u00c1., Szita, V.R., Horv\u00e1th, R., Szederjesi, A., Seb\u0151, A., T\u00f3th, A.D., Masszi, T., and Varga, G. (2023). Soluble B-cell maturation antigen as a monitoring marker for multiple myeloma. Pathol. Oncol. Res., 29.","DOI":"10.3389\/pore.2023.1611171"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1186\/s13287-020-02032-8","article-title":"Comprehensive proteomic analysis of exosomes derived from human bone marrow, adipose tissue, and umbilical cord mesenchymal stem cells","volume":"11","author":"Wang","year":"2020","journal-title":"Stem Cell Res. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s13287-021-02405-7","article-title":"Proteomic analysis of bone marrow-derived mesenchymal stem cell extracellular vesicles from healthy donors: Implications for proliferation, angiogenesis, Wnt signaling, and the basement membrane","volume":"12","author":"McBride","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.jcyt.2022.08.009","article-title":"Proteomics profile of mesenchymal stromal cells and extracellular vesicles in normoxic and hypoxic conditions","volume":"24","author":"Braga","year":"2022","journal-title":"Cytotherapy"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jprot.2015.12.016","article-title":"Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers","volume":"136","author":"Harshman","year":"2016","journal-title":"J. Proteom."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project","volume":"40","author":"Cairns","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1038\/s41467-022-32145-y","article-title":"The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states","volume":"13","author":"Rasche","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/blood.V85.6.1442.bloodjournal8561442","article-title":"Interleukin-5 signaling in human eosinophils involves JAK2 tyrosine kinase and Stat1 alpha","volume":"85","author":"Caldenhoven","year":"1995","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/intimm\/8.2.237","article-title":"Critical proline residues of the cytoplasmic domain of the IL-5 receptor alpha chain and its function in IL-5-mediated activation of JAK kinase and STAT5","volume":"8","author":"Kouro","year":"1996","journal-title":"Int. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000237712","article-title":"The activation of the JAK2\/STAT5 pathway is commonly involved in signaling through the human IL-5 receptor","volume":"114","author":"Ogata","year":"1997","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/s41375-018-0117-x","article-title":"Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer","volume":"32","author":"Wingelhofer","year":"2018","journal-title":"Leukemia"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N. Engl. J. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/7\/1116\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T04:38:57Z","timestamp":1775191137000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/7\/1116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":45,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["cancers18071116"],"URL":"https:\/\/doi.org\/10.3390\/cancers18071116","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]}}}